|
INVESTOR CENTER
DOR
BioPharma, Inc.’s common stock is listed on the Over
-The- Counter bulletin board securities market under
the symbol “DORB”. Stockholders and interested parties
are urged to contact our main office in Ewing, New Jersey at 609-538-8200 for further information.
FINANCIAL
INFORMATION
DOR
BioPharma Stock Quote
(Over -The- Counter bulletin
board securities market, symbol “DORB” ).
DOR
BioPharma Filings with the SEC (link
to EDGAR DATABASE)
DOR
BioPharma Financial Releases
Code
of Ethics for Senior Financial Officers
10QSB
Provides a comprehensive review of DOR BioPharma's financial
position and operating results for the quarter and year-to-date.
Offers a discussion of business activities, information
about earnings and other measures of financial performance
and unaudited financial statements and statistical data.
LINK
to 10QSB on the EDGAR database
10KSB
Provides a description of DOR BioPharma's businesses,
products and services, a comprehensive review of the
company's financial position and operating results for
the year, a discussion of business activities, information
about earnings and other measures of financial performance
and audited financial statements and footnotes.
LINK
to 10KSB on the EDGAR database
LITERATURE
REQUEST:
If
you would like to receive our Investor Relations Packet,
including reprints of scientific publications relating
to our products, please fill out the following form
and click on “Submit”. Thank you for your
interest.
| |
|
| |
The Private Securities Litigation Reform Act of
1995 provides a "safe harbor" for certain
forward-looking statements. The forward-looking
statements contained in this release are subject
to certain risks and uncertainties. Actual results
could differ materially from current expectations.
Among the factors which could affect the Company's
actual results and could cause results to differ
from those contained in the forward-looking statements
contained herein are: the timely commencement
and success of the Company's clinical trials and
other research endeavors, delays in receiving
FDA or other regulatory approvals, the development
of competing therapies and/or technologies, the
terms of any future strategic alliances, the possible
need for additional capital, and any additional
factors described from time to time in the Company’s
periodic reports on Form 10-KSB and 10-QSB, and
any prospectus describing the Company’s securities.
Links
to Third Party Sites:
Please understand that when you access another
web site through this one, DOR BioPharma can accept
no responsibility for your experience with the
site. In addition, a link to a non-DOR BioPharma
site does not mean that DOR BioPharma endorses
or recommends that site or its contents.
Stock
Information:
The information provided under "DOR BioPharma
Stock Quote" in the Investor Center section
of this site is provided through a hypertext link
to a third party Web site. (See above for important
information about links to third party Web sites.)
Under no circumstances will DOR BioPharma be liable
for any loss or direct, indirect, incidental,
special or consequential damages caused by reliance
on this information or for the risks of the stock
market.
|
|
